Methods and uses for treating anhedonia
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11957675-B2
Publication Date
2024-04-16
Expiration Date
Abstract
The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
Core Innovation
The invention is directed to methods of treating anhedonia in a human by administering Compound A. Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide. The treatment comprises administering a therapeutically effective amount of Compound A to a human in need thereof for anhedonia.
The disclosed approach is also directed to reversing hyperactivity in the ventral tegmental area (VTA) by administering Compound A to a human suffering from anhedonia. The patent content further links the approach to selective enhancement of Kv7 potassium channel opening, including Kv7.2 and Kv7.3, with comparisons to Kv7.1.
The patent content reports behavioral and motivational measures consistent with improved anhedonia-related performance in a rodent Progressive Ratio Test, including lever press and break point outcomes. The content further indicates that the effects are observed particularly in “low” responder animals at specified dosing conditions versus vehicle, with a comparison reference to D-amphetamine.
Claims Coverage
The partial content includes two independent claims. Across these claims, there are two main inventive features.
Treating anhedonia by administering Compound A
A method of treating anhedonia comprising administering a therapeutically effective amount of Compound A to a human in need thereof, wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.
Reversing VTA hyperactivity in anhedonia using Compound A
A method of reversing hyperactivity in the ventral tegmental area (VTA) comprising administering an effective amount of Compound A to a human in need thereof, wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide, and wherein the human is suffering from anhedonia.
The independent claims cover Compound A as a defined small molecule administered to humans to treat anhedonia and to reverse hyperactivity in the ventral tegmental area in humans suffering from anhedonia.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment of anhedonia in a human.
Reversing hyperactivity in the ventral tegmental area (VTA) in a human suffering from anhedonia.
Interested in licensing this patent?